EcoDrugPlus

Cytochrome P450 3a40

Ensembl ID : ENSACLG00000002304
Gene Symbol: LOC113024448
3 Cross references
563 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSACLG00000025483
Gene Symbol: LOC113035333
2 Cross references
544 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSACLG00000008094
Gene Symbol: CYP19A1
3 Cross references
242 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSACLG00000009748
Gene Symbol: CYP19A1
1 Cross references
243 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSACLG00000010505
Gene Symbol: CYP19A1
4 Cross references
243 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSACLG00000001386
Gene Symbol: CYP3A65
1 Cross references
564 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSACLG00000022417
Gene Symbol: LOC113035071
3 Cross references
215 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSACLG00000009387
Gene Symbol: LOC113014833
2 Cross references
195 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSACLG00000013409
Gene Symbol: LOC113010792
3 Cross references
200 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSACLG00000012220
Gene Symbol: DGAT1
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSACLG00000007146
Gene Symbol: LOC113032298
3 Cross references
187 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSACLG00000025370
Gene Symbol: DHODH
3 Cross references
173 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).